Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Kirkham

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Rheumatology Advances in Practice|August 22, 2019
Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective studyGavin Clunie, Iain B McInnes, Nick Barkham, et al.
The New England Journal of Medicine|October 1, 2015
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic ArthritisPhilip J Mease, Iain B McInnes, Bruce Kirkham, et al.
The Lancet. Rheumatology|January 25, 2024
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 studyIain B McInnes, Philip J Mease, Alan J Kivitz, et al.
Spine|November 17, 2006
The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trialTimo Korhonen, Jaro Karppinen, Leena Paimela, et al.
The Lancet. Rheumatology|December 21, 2020
Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional studyPhilippa M Wells, Adewale S Adebayo, Ruth C E Bowyer, et al.
Lancet (London, England)|July 3, 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialIain B McInnes, Philip J Mease, Bruce Kirkham, et al.
Pain Reports|June 24, 2025
Validity and contributions to pain from the central aspects of pain questionnaire in rheumatoid arthritisStephanie Louise Smith, Vasileios Georgopoulos, Onosi Sylvia Ifesemen, et al.
Current Medical Research and Opinion|June 18, 2025
Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: final analysis from a prospective observational cohort study (ENDEAVOUR)James Taylor, Srinivasan Srirangan, Marwan Bukhari, et al.
Arthritis and Rheumatism|April 9, 2005
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, et al.
Rheumatology (Oxford, England)|December 9, 2025
Development of a psoriatic arthritis - like presentation under anti - IL-13 therapy with tralokinumab for atopic dermatitisKatya Meridor, Sook Yan Lee, Ilona Blee, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Rheumatology Advances in Practice|August 22, 2019
Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective studyGavin Clunie, Iain B McInnes, Nick Barkham, et al.
The New England Journal of Medicine|October 1, 2015
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic ArthritisPhilip J Mease, Iain B McInnes, Bruce Kirkham, et al.
The Lancet. Rheumatology|January 25, 2024
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 studyIain B McInnes, Philip J Mease, Alan J Kivitz, et al.
Spine|November 17, 2006
The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trialTimo Korhonen, Jaro Karppinen, Leena Paimela, et al.
The Lancet. Rheumatology|December 21, 2020
Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional studyPhilippa M Wells, Adewale S Adebayo, Ruth C E Bowyer, et al.
Lancet (London, England)|July 3, 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialIain B McInnes, Philip J Mease, Bruce Kirkham, et al.
Pain Reports|June 24, 2025
Validity and contributions to pain from the central aspects of pain questionnaire in rheumatoid arthritisStephanie Louise Smith, Vasileios Georgopoulos, Onosi Sylvia Ifesemen, et al.
Current Medical Research and Opinion|June 18, 2025
Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: final analysis from a prospective observational cohort study (ENDEAVOUR)James Taylor, Srinivasan Srirangan, Marwan Bukhari, et al.
Arthritis and Rheumatism|April 9, 2005
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, et al.
Rheumatology (Oxford, England)|December 9, 2025
Development of a psoriatic arthritis - like presentation under anti - IL-13 therapy with tralokinumab for atopic dermatitisKatya Meridor, Sook Yan Lee, Ilona Blee, et al.
Pageof 6